Official Policy AnswersUpdated for 2026 Telehealth Enforcement

Telehealth Weight Loss & GLP-1 Ad Compliance FAQ

Direct Regulatory Answer:

Advertising compounded Semaglutide and Tirzepatide is permitted on Meta, Google, and TikTok only when your business holds active LegitScript certification and references active pharmaceutical ingredients rather than patented brand names. Every campaign must prominently disclose that prescriptions require a licensed telehealth physician evaluation and cannot guarantee specific poundage or timeframe outcomes.

Key 2026 Policy Enforcement Benchmarks

  • Direct promotion of patented brand names (Ozempic®, Wegovy®, Zepbound®) for compounded medications is prohibited under trademark and pharmaceutical policy.
  • LegitScript Healthcare Merchant certification is required before running any prescription weight loss ads in the United States.
  • Before-and-after photos, tape measure imagery, and extreme body close-ups trigger automated Computer Vision ad rejections on Meta.
  • Adlexa provides instant pre-flight AI auditing to guarantee copy, visuals, and landing pages meet all 2026 regulatory thresholds before spend.

Banned vs. Compliant Weight Loss Copy Phrasing

Exact headline and copy rewrites tested against Meta, Google, and FDA 503A review bots.

Trigger / Banned CopyCompliant Adlexa RewriteViolation Reason
"Buy Generic Ozempic Online"
"Doctor-supervised compounded Semaglutide programs, if clinically appropriate"
Trademark infringement + Unapproved generic claim
"Lose 30 lbs in 30 days guaranteed"
"Personalized medical weight management plans tailored to your health history"
Absolute outcome guarantee + Misleading medical efficacy
"Struggling with your heavy belly fat?"
"Discover how modern clinical telehealth approaches metabolic health"
Personal health attributes & negative self-perception trigger
"No prescription needed, instant shipping"
"Requires comprehensive clinical evaluation by a state-licensed healthcare provider"
Illegal prescription dispensing claim + LegitScript disqualifier
"FDA-Approved Compounded Tirzepatide"
"Compounded Tirzepatide formulated in state-licensed 503A pharmacies (not FDA approved)"
False FDA approval representation (503A compounding violation)

Complete Question & Answer Directory

Yes, but advertisers must hold active LegitScript Healthcare Merchant certification and avoid using registered trademarks (Ozempic®, Wegovy®, Mounjaro®) to describe compounded alternatives. Copy must strictly state that medications require a physician consultation, cannot promise guaranteed poundage or specific timeframes, and must clearly disclose that compounded formulations are not FDA-approved brand generics.
Comprehensive Breakdown

Read our full breakdown of GLP-1 & Compounded Semaglutide Advertising

Includes full Lanham Act trademark analysis and Meta personal attributes guidance.

Pre-Screen Your Weight Loss Campaigns with Adlexa

Audit your ad headlines, body copy, and landing page URLs in seconds before risking your Meta or Google ad account.